麻豆传媒

Geriatrics >

CHF

News, opinions and meeting coverage in geriatrics.

'Hmm, Maybe I Don't Want an LVAD'

Trial intervention's better-informed patients were less likely to opt for device

'Good Doctor,' Bad Cardiology

John Higgins, MD, explains some aspects of medicine the ABC show got wrong

Afib and Ablation; Herbs and Drugs: This Week's PodMed Double T

This week's topics include herb/drug interactions, Afib and ablation in congestive heart failure, clot retrieval in stroke, and childhood kidney disease and adult end-stage renal disease

Pearls From: Ulrich Jorde, MD

'Get over your ego' and let the heart team in

The Stiffer the Liver, The Worse the HF Prognosis

Study suggests transient elastography of liver is prognostic

MRI May Still be OK for Legacy Cardiac Devices

Safety protocols are key, researchers say

'Normal' LVEF: Misnomer in Aortic Stenosis?

Study shows survival in severe aortic stenosis impaired with LVEF

Do the Russians Always Cheat?

Milton Packer provides a perspective on the meaning of truth in medicine and in life.

Can Industry-Funded Research Be Trusted?

Milton Packer wonders who is really trustworthy

Survival Not Better When Patients Have ICD Plus Newer LVAD

Combo may even be associated with harm, registry suggests

Move to Get Benicar Off Market; Nexterone Recall; Squirrel Hibernation Stroke Tx?

Recent developments of interest in cardiovascular medicine

AHA: For CIED Surgery, NOAC Administration Up to Clinician

Continued or interrupted therapy carried same risk of clinically significant hematoma development

AHA: ACA Program Offers Mixed Results for HF Readmits

HRRP tied to less readmissions, but seems to up mortality

Who Actually Is Reviewing All Those Preauthorization Requests?

Milton Packer thinks you should know how the system works

Borderline Pulmonary Hypertension Tied to Mortality Risk

Small increases in pressure might signal left heart failure, not early PAH

Supplements Affect NT-ProBNP; Cord Stem Cells; ED Exit Sans Stress Test

Cardiovascular Daily wraps up the top cardiology news of the week

Entresto Boosts Sex in HF; Venom Antidote to Xa Drugs; Guilty Plea for FH Vagueness

Recent developments of interest in cardiovascular medicine

HF Monitor Trips on PA Injury in Postmarket Surveillance

Reintervention or device recalibration often needed after PA injury

TTR Cardiomyopathy Easily Detected By Biceps Bunching

Biceps tendon rupture may be a clue to HF cause

ESC: Merck REVEALS a Slightly Positive CETP Inhibitor Trial

A CETP inhibitor scores after 3 strikes for the class

Inflammation, Secondary Prevention, Diet in Spotlight at ESC

CANTOS, COMPASS, PURE will headline the world's largest cardiology meeting

Guidance Issued on PET Imaging in Diagnosing Cardiac Sarcoidosis

ASNC, SNMMI release recommendations for difficult diagnostic challenge

Studies Stop Short of Quelling TAVR Durability Fears

Structural valve deterioration observed in 3.9% over 5 years

Does Longer TAVR Time Make Stroke More Likely?

SURTAVI neuro substudy bolsters comparability between TAVR, SAVR

Lotus TAVR Device Again Trips Up on Pacemaker Rate

Otherwise, efficacy superior overall against CoreValve in REPRISE III trial

As Hospital TAVR Volume Goes Up, Readmits Go Down

Is it time for TAVR regionalization?

Lower BP Targeted in New Heart Failure Guidelines

ACC/AHA/HFSA recommend adjusted SPRINT target of

CardioBrief: Serious Questions Raised About Validity Of International Trials

TOPCAT analysis is the 'smoking gun' for trouble from 'offshoring' trials

Best (Musical) Beats for CPR Training (CNN)

Synchrony with CPR components essential

Dosing Crucial for Digoxin, Warfarin Safety

Digoxin unsafe at high levels regardless of heart failure

SURTAVI: TAVR Matches Surgery in Lowest-Risk Cohort

But reinterventions, parvalvular regurgitation, and pacemaker implants mar a supposed victory

Everyday Exposure to EM Fields Can Disrupt Pacemakers

Lower sensitivity and bipolar sensing recommended

Wise Buy? Left Ventricular Assist Devices

Getting better and cheaper, but 'nobody wears pink ribbons for heart failure'

Subclavian TAVR Safe When Femoral Access Is Risky

Trial analysis shows similar morbidity, mortality

SAVR Beats Expectations in Intermediate Risk Trial

Lower mortality than surgical risk score predicted in PARTNER 2A

Novartis Pulls Out of Controversial Entresto Contest

Cardiologists named to review panel had quit

CMS to Offer Billing Code for Heart Failure Specialists

Should eliminate denials for appearance of double-billing

Trial: No Benefit for High-Dose Diuretic in Acute HF

But phase II results might not be the final word

AHA: No Pump Thrombosis With Next-Gen LVAD?

Better outcomes in HeartMate 3 trial hinged on fewer malfunctions

AHA: Real World TAVR Is All About Patient Selection

Intermediate risk is a moving target

鈥�

12